- SEK117.62m
- SEK104.24m
- SEK156.81m
- 91
- 74
- 10
- 62
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 7.49 | ||
| PEG Ratio (f) | 0.4 | ||
| EPS Growth (f) | 22.92% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.98 | ||
| Price to Tang. Book | 2.88 | ||
| Price to Free Cashflow | 9.75 | ||
| Price to Sales | 0.75 | ||
| EV to EBITDA | 4.98 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 23.01% | ||
| Return on Equity | 20.7% | ||
| Operating Margin | 8.71% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 117.42 | 117.13 | 125.05 | 163.01 | 156.81 | 190 | 204 | 3.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -67.7 | n/a | n/a | +17.93 | +220.29 | +28.22 | +14.04 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arcoma AB is a Sweden-based medical technology company. It develops, produces and markets digital radiographic systems. Its products offer digital imaging technology combined with advanced mobile positioning system. The Company's product portfolio comprises: complete radiographic systems available as ceiling suspensions and floor mounted systems, as well as detectors; radiographic system components, such as overhead tube crane, cube, tilting wall stand and radiographic tables; and mobile imaging tables in two series, namely Precision and Elite. Its products are designed for hospitals, clinics, imaging centers and private practices, and available through three market channels: its own brand IMIX, private label distributors and original equipment manufacturers (OEM).
Directors
- Lars Kvarnhem CHM (49)
- Sanna Rydberg CEO (52)
- Johan Henningsson VRD (50)
- Mattias Rundgren CTR (43)
- Frida Robbe DMK (36)
- Nicklas Johansson OTH (54)
- Katja Kristensson OTH (38)
- Jesper Lindroos OTH (37)
- Linda Ungsten OTH (47)
- Anders Dahlberg DRC (45)
- Jesper Soderqvist DRC (55)
- Mats Thoren DRC (50)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 11th, 1990
- Public Since
- November 14th, 2014
- No. of Employees
- 31
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
OMX Nordic Exchange Stockholm- Shares in Issue
- 13,185,560
- Address
- Annavagen 1, VAXJO, 352 46
- Web
- https://www.arcoma.se/
- Phone
- +46 470706900
- Auditors
- Access Revision AB
Upcoming Events for ARCOMA
Arcoma AB Annual Shareholders Meeting
Q2 2025 Arcoma AB Earnings Release
Q3 2025 Arcoma AB Earnings Release
Similar to ARCOMA
Acarix AB
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
ADDvise AB (publ)
OMX Nordic Exchange Stockholm
Arjo AB (publ)
OMX Nordic Exchange Stockholm
FAQ
What is the Arcoma AB share price?
As of Today at 19:19 UTC, shares in Arcoma AB are trading at SEK8.92. This share price information is delayed by 15 minutes.
How has the Arcoma AB share price performed this year?
Shares in Arcoma AB last closed at SEK8.92 and the price had moved by -32.17% over the past 365 days. In terms of relative price strength the Arcoma AB share price has underperformed the FTSE Global All Cap Index by -33.87% over the past year.
What are the analyst and broker recommendations for Arcoma AB?
There is no consensus recommendation for this security.
Find out moreWhat is the Arcoma AB dividend yield?
Arcoma AB does not currently pay a dividend.
Does Arcoma AB pay a dividend?
Arcoma AB does not currently pay a dividend.
When does Arcoma AB next pay dividends?
Arcoma AB does not currently pay a dividend.
How do I buy Arcoma AB shares?
To buy shares in Arcoma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Arcoma AB?
As of the previous close price of SEK8.92, shares in Arcoma AB had a market capitalisation of SEK117.62m.
Where are Arcoma AB shares listed?
Here are the trading details for Arcoma AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: ARCOMA
What kind of share is Arcoma AB?
Based on an overall assessment of its quality, value and momentum Arcoma AB is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Arcoma AB share price forecast for 2025?
The analyst consensus target price for shares in Arcoma AB is SEK15.67. That is 75.67% above the last closing price of SEK8.92.
Analysts covering Arcoma AB currently have a consensus Earnings Per Share (EPS) forecast of SEK1.14 for the next financial year.
Find out moreWhat is the trend in the Arcoma AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arcoma AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -24.18%.
As of the last closing price of SEK8.92, shares in Arcoma AB were trading -28.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Arcoma AB PE Ratio?
The Arcoma AB PE ratio based on its reported earnings over the past 12 months is 7.49. The shares last closed at SEK8.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Arcoma AB?
Arcoma AB's management team is headed by:
- Lars Kvarnhem - CHM
- Sanna Rydberg - CEO
- Johan Henningsson - VRD
- Mattias Rundgren - CTR
- Frida Robbe - DMK
- Nicklas Johansson - OTH
- Katja Kristensson - OTH
- Jesper Lindroos - OTH
- Linda Ungsten - OTH
- Anders Dahlberg - DRC
- Jesper Soderqvist - DRC
- Mats Thoren - DRC